Results 151 to 160 of about 582,181 (313)

The Osteoblastic Microenvironment Determines the Fate of Breast Cancer Cells Disseminated in the Bone Marrow

Advanced Science, EarlyView.
This study revealed how the osteoblastic microenvironment determines the fate of cancer cells disseminated in bone, with a focus on whether they colonize, reside in quiescence, or reactivate from dormancy. Targeting integrin signaling may offer promising strategies for preventing quiescent cancer cells reactivation and bone colonization.
Hong‐Li Wang, Rui Zhang, Xiao‐Min Yue, Jie Zhou, Yu‐Fan Huang, Rong Meng, Yu‐Li Wang, Xiao‐Qing Li   +7 more
wiley   +1 more source

Anifrolumab-A Potential New Systemic Sclerosis Treatment. [PDF]

J Clin Med
Radić M, Prižmić PŠ, Bečić T, Đogaš H, Perković D, Radić J, Fabijanić D.   +6 more
europepmc   +1 more source

DOES INTERFERON (IFN)S EXIST IN CRUSTACEA?

, 2011
Dewi Syahidah, Leigh Owens
openalex   +2 more sources

Normal full‐term pregnancy in a patient with chronic myelogenous leukemia treated with α‐interferon [PDF]

, 1991
Maria R. Baer
openalex   +1 more source

Biodegradable Carbonate Nanogels Loaded with Anti MFAP‐5 siRNA for Anti‐stromal Therapy of Hepatocellular Carcinoma

Advanced Science, EarlyView.
Polycarbonate nanogels enable lipid‐free delivery of anti‐MFAP‐5 siRNA into cancer‐associated fibroblasts (CAF) in hepatocellular carcinoma. In a cirrhotic murine model, this approach silences MFAP‐5, reduces fibroblast activation, and suppresses tumor growth by inhibiting NOTCH/Hes1‐driven angiogenesis. CAF‐targeted MFAP‐5 RNAi and conserved signaling
Paul Schneider, Alexander Fuchs, Michael Fichter, Vanessa Bolduan, Jenny Schunke, Özlem Akilli, Nádia C. Correia, Yannick Ehlers, Christian Czysch, Pia Winterwerber, Eliana Stanganello, Barbara Schrörs, Mustafa Diken, Christoph Eckert, Shusruto Rishik, Andreas Keller, Jörn M. Schattenberg, Stephan Grabbe, Matthias Bros, Lutz Nuhn, Leonard Kaps   +20 more
wiley   +1 more source

Oligoprotein type I interferon signatures, but not TREX1 variants, increase risk of systemic lupus erythematosus in UK Biobank. [PDF]

Nat Commun
Rioux B, McGlasson S, Forbes D, Reid KR, Klingseisen A, Berry J, Dhaun N, Ng WF, Whiteley W, Hunt DPJ.   +9 more
europepmc   +1 more source

Redefining Dendritic Cell Vaccines: Synergistically Co‐priming DC and B Cells With Nanoparticles Loading Whole Cell Antigens Maximizes the Efficacy of DC Vaccines

Advanced Science, EarlyView.
Dendritic cells (DC) vaccine is an important type of vaccines. However, the limited efficacy of DC vaccines hinders their widely application. This study redefines DC vaccines and provides a new DC‐BC vaccine that have much better therapeutic efficacy.
Xiangxiang Xu, Xianlan Chen, Jin Wang, Yuhan Liu, Sidra Mustafa, Lu Diao, Rongrong Zhao, Haiyang Chi, Kang Hu, Jiashan Zhu, Jun Zhao, Mi Liu   +11 more
wiley   +1 more source

Add-on PD-1 inhibitor with Peg-IFNα therapy favors functional cure of chronic hepatitis B patients. [PDF]

J Transl Int Med
Li Y, Liu C, Yang L, He L, Li M, Gou G, Feng D, Zhang X, Wang F, Fu J, Dang S.   +10 more
europepmc   +1 more source

RNF213 Is an Interferon‐Stimulated Gene That Targets Influenza A Virus NP and Activates MDA5 to Restrict Infection

Advanced Science, EarlyView.
RNF213 is characterized as a dual‐functional antiviral effector. It directly mediates the degradation of the influenza A virus nucleoprotein (NP) while simultaneously activating the MDA5‐mediated innate immune signaling pathway. This coordinated response establishes a powerful host defense system against viral infection. ABSTRACT Influenza A virus (IAV)
Haoning Li, Yuying Zhang, Jingjing Wang, Qianqian Zhang, Hailiang Sun, Fanhua Wei   +5 more
wiley   +1 more source

Negative Regulator of Interferon Response Promotes Toll-like Receptor 3-induced Interleukin 6 in Rheumatoid Synoviocyte. [PDF]

In Vivo
Wada K, Imaizumi T, Ishibashi HK, Nakamura Y, Saruga T, Kawaguchi S, Tachizaki M, Oishi K, Sasaki E, Wada K, Ishibashi Y.   +10 more
europepmc   +1 more source